≥50岁与<50岁重型再生障碍性贫血患者接受阿仑单抗为基础移植的结局相似
这项回顾性研究纳入65例获得性重型再生障碍性贫血(SAA)患者,均接受氟达拉滨、低剂量环磷酰胺和阿仑单抗(FCC)方案移植,比较27例≥50岁与38例<50岁患者的结局。
要点
- 两组急慢性GVHD及移植相关死亡率均低且相似。
核心结论
- ≥50岁SAA患者接受FCC移植的结局与<50岁患者相似,合并症而非年龄可能是更适合评估移植适宜性的决定因素。
研究设计与样本
- 回顾性研究纳入65例连续接受FCC方案(氟达拉滨、低剂量环磷酰胺、阿仑单抗)移植的获得性SAA患者。
- 27例年龄≥50岁(中位61岁,范围51-71岁),38例<50岁;老年组21例(78%)接受无关供者移植(其中3例HLA 9/10错配),6例接受同胞全合供者移植。
主要发现
- 急性GVHD发生率两组分别为5%与4%,慢性GVHD分别为18%与14%,匹配供者移植中无重度GVHD病例。
- ≥50岁组供者T细胞嵌合率中位1年64%、3年60%,与年轻患者相似;B调节细胞增加可能有助于低异体反应性和供受者相互耐受。
临床怎么用
- 对≥50岁SAA患者,FCC移植可作为可选方案,但需重点评估合并症(HCT-CI)而非仅凭年龄排除。
局限性
- 回顾性研究,样本量较小(65例),≥50岁组仅27例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Survival after allogeneic hematopoietic cell transplantation (HSCT) for severe aplastic anemia (SAA) among older patients remains poor and associated with increased risk for graft-versus-host disease (GVHD). In this retrospective study of 65 consecutive patients with acquired SAA who were transplanted using fludarabine, low-dose cyclophosphamide, and alemtuzumab (FCC), outcomes of 27 patients aged at least 50 years were compared with those of 38 patients younger than 50 years. The median age of the older cohort was 61 years (range, 51-71 years); 21 (78%) patients were transplanted from unrelated donors (3 of 21 from HLA 9/10 mismatch donors) and 6 from matched sibling donors. One-year GVHD-free, relapse-free survival (GRFS) was comparable to that of patients younger than 50 years (84% vs 94%, respectively; P = .23). Both groups showed low rates of acute (5% vs 4%) and chronic (18% vs 14%) GVHD, with no cases of severe GVHD among matched donor transplants, and similar 1-year transplant-related mortality (14% vs 5.4%, older vs younger; P = .23). HSCT comorbidity index (HTC-CI) scores were similar between the groups, but overall survival with an HCT-CI of at least 3 was lower compared with a score less than 3 (76% vs 98%; P = .005). Median donor T-cell chimerism among older patients was 64% and 60% at 1 and 3 years, respectively, and was similar to that of younger patients. Increased B regulatory cells potentially contributed to low alloreactivity and mutual donor-recipient tolerance in older patients. Effect of comorbidities rather than age alone may be a more important determinant of suitability for FCC HSCT in older patients.
引用
- Sheth VS, Potter V, Gandhi SA, et al. Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years. Blood Adv. 2019. PMID: 31648330. doi:10.1182/bloodadvances.2019000480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。